Ken Fisher
GTHX

Ken Fisher’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Ken Fisher’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,543,006
Closed -$6.33M – 1273
2023
Q2 		$6.33M Sell
2,543,006
-180,896
-7% -$494K ﹤0.01% 514
2023
Q1 		$7.3M Sell
2,723,902
-85,542
-3% -$411K ﹤0.01% 494
2022
Q4 		$15.3M Sell
2,809,444
-125,888
-4% -$1.06M 0.01% 384
2022
Q3 		$36.7M Buy
2,935,332
+626,777
+27% +$7.16M 0.03% 272
2022
Q2 		$11.4M Sell
2,308,555
-2,583
-0.1% -$14.3K 0.01% 346
2022
Q1 		$17.6M Buy
2,311,138
+43,064
+2% +$408K 0.01% 323
2021
Q4 		$23.2M Buy
2,268,074
+529,863
+30% +$6.75M 0.01% 309
2021
Q3 		$23.3M Buy
1,738,211
+823,373
+90% +$13.4M 0.01% 301
2021
Q2 		$20.1M Buy
+914,838
New +$20.3M 0.01% 317

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Ken Fisher's GTHX Position: Q3 2023 in Review

Ken Fisher sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2023, closing a stake of 2,543,006 shares — an estimated $6.33M sold.

Ken Fisher first reported a position in GTHX in Q2 2021 and held it in 9 quarters. The position peaked at $36.7M in Q3 2022. 72 funds tracked by Wall St. Rank hold GTHX as of Q3 2023.

  • Ken Fisher reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ken Fisher sold 2,543,006 G1 Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $6.33M.
  • Ken Fisher first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
  • Ken Fisher's G1 Therapeutics, Inc. Common Stock position peaked at $36.7M in Q3 2022.
  • 72 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.